سوق المخدرات خزل المعدة - النمو والاتجاهات وتأثير COVID-19 والتنبؤات (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Assumptions

   2. 1.2 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Market Drivers

      1. 4.2.1 Increase in the Incidence Rate of Diabetes

      2. 4.2.2 Rise in Number of Surgeries

      3. 4.2.3 Growth in Geriatric Population

   3. 4.3 Market Restraints

      1. 4.3.1 Time-consuming Regulatory Process

      2. 4.3.2 Side Effects of Gastroparesis Drugs

   4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Drug Class

      1. 5.1.1 Antiemetic Agents

      2. 5.1.2 Prokinetic Agents

      3. 5.1.3 Botulinum Toxin Injections

   2. 5.2 By Disease Type

      1. 5.2.1 Diabetic Gastroparesis

      2. 5.2.2 Post-Surgical Gastroparesis

      3. 5.2.3 Idiopathic Gastroparesis

      4. 5.2.4 Other Disease Types

   3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Pharmacies

   4. 5.4 Geography

      1. 5.4.1 North America

         1. 5.4.1.1 United States

         2. 5.4.1.2 Canada

         3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

         1. 5.4.2.1 Germany

         2. 5.4.2.2 United Kingdom

         3. 5.4.2.3 France

         4. 5.4.2.4 Italy

         5. 5.4.2.5 Spain

         6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

         1. 5.4.3.1 China

         2. 5.4.3.2 Japan

         3. 5.4.3.3 India

         4. 5.4.3.4 Australia

         5. 5.4.3.5 South Korea

         6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

         1. 5.4.4.1 GCC

         2. 5.4.4.2 South Africa

         3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

         1. 5.4.5.1 Brazil

         2. 5.4.5.2 Argentina

         3. 5.4.5.3 Rest of South America

6. 6. COMPETITIVE LANDSCAPE

   1. 6.1 Company Profiles

      1. 6.1.1 Abbott (Abbott Arzneimittel GmbH)

      2. 6.1.2 Allergan Plc

      3. 6.1.3 Cadila Pharmaceuticals

      4. 6.1.4 Evoke Pharma

      5. 6.1.5 AstraZeneca Plc

      6. 6.1.6 Neurogastrx Inc.

      7. 6.1.7 Bausch Health

      8. 6.1.8 Theravance Biopharma

      9. 6.1.9 GlaxoSmithKline Plc

   *List Not Exhaustive

7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS